NASDAQ:GLPG - GALAPAGOS NV/S Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding GALAPAGOS NV/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $216.42 -17.49 (-7.48 %) (As of 02/28/2020 01:30 AM ET) Add Compare Today's Range$209.00Now: $216.42▼$222.0850-Day Range$208.26MA: $238.67▼$274.0352-Week Range$94.75Now: $216.42▼$274.03Volume376,828 shsAverage Volume175,265 shsMarket Capitalization$11.86 billionP/E Ratio42.77Dividend YieldN/ABeta1.57 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GLPG Previous Symbol CUSIPN/A CIK1421876 Webhttp://www.glpg.com/ Phone321-534-2900Debt Debt-to-Equity Ratio0.01 Current Ratio8.95 Quick Ratio8.95Price-To-Earnings Trailing P/E Ratio42.77 Forward P/E Ratio30.74 P/E GrowthN/A Sales & Book Value Annual Sales$375.54 million Price / Sales31.59 Cash FlowN/A Price / Cash FlowN/A Book Value$27.99 per share Price / Book7.73Profitability EPS (Most Recent Fiscal Year)($0.66) Net Income$-34,560,000.00 Net Margins32.09% Return on Equity25.34% Return on Assets15.38%Miscellaneous EmployeesN/A Outstanding Shares54,820,000Market Cap$11.86 billion Next Earnings DateN/A OptionableOptionable Receive GLPG News and Ratings via Email Sign-up to receive the latest news and ratings for GLPG and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:GLPG Rates by TradingView GALAPAGOS NV/S (NASDAQ:GLPG) Frequently Asked Questions What is GALAPAGOS NV/S's stock symbol? GALAPAGOS NV/S trades on the NASDAQ under the ticker symbol "GLPG." What price target have analysts set for GLPG? 14 brokerages have issued 12 month price targets for GALAPAGOS NV/S's stock. Their forecasts range from $169.00 to $302.00. On average, they expect GALAPAGOS NV/S's stock price to reach $227.70 in the next twelve months. This suggests a possible upside of 5.2% from the stock's current price. View Analyst Price Targets for GALAPAGOS NV/S. What is the consensus analysts' recommendation for GALAPAGOS NV/S? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GALAPAGOS NV/S in the last year. There are currently 3 sell ratings, 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GALAPAGOS NV/S. Has GALAPAGOS NV/S been receiving favorable news coverage? News stories about GLPG stock have been trending very negative this week, InfoTrie reports. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. GALAPAGOS NV/S earned a coverage optimism score of -3.2 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days. View News Stories for GALAPAGOS NV/S. Who are some of GALAPAGOS NV/S's key competitors? Some companies that are related to GALAPAGOS NV/S include ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Teva Pharmaceutical Industries (TEVA), Alnylam Pharmaceuticals (ALNY), Ono Pharmaceutical (OPHLF), Elanco Animal Health (ELAN), Mylan (MYL) and Beigene (BGNE). What other stocks do shareholders of GALAPAGOS NV/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other GALAPAGOS NV/S investors own include Gilead Sciences (GILD), argenx (ARGX), CELYAD SA/ADR (CYAD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Pharming Group (PHGUF), Collegium Pharmaceutical (COLL), Trade Desk (TTD), Sociedad Quimica y Minera de Chile (SQM) and Celgene (CELG). Who are GALAPAGOS NV/S's key executives? GALAPAGOS NV/S's management team includes the folowing people: Mr. Onno van de Stolpe, Co-Founder, MD, CEO & Exec. Director (Age 60)Mr. Bart Filius MBA, CFO & COO (Age 49)Dr. Piet Wigerinck, Chief Scientific Officer (Age 55)Ms. Elizabeth Goodwin, VP of Investor Relations & Corp. CommunicationsDr. Andre Hoekema, Chief Bus. Officer (Age 62) When did GALAPAGOS NV/S IPO? (GLPG) raised $161 million in an IPO on Thursday, May 14th 2015. The company issued 3,800,000 shares at $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company served as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers. Who are GALAPAGOS NV/S's major shareholders? GALAPAGOS NV/S's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Sands Capital Management LLC (4.82%), FMR LLC (1.10%), Bessemer Group Inc. (0.49%), Jane Street Group LLC (0.17%), Public Employees Retirement Association of Colorado (0.15%) and Bank of America Corp DE (0.12%). Which institutional investors are selling GALAPAGOS NV/S stock? GLPG stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG, Eventide Asset Management LLC, Sands Capital Management LLC, Bessemer Group Inc., Bank of America Corp DE, Bank of New York Mellon Corp, FMR LLC and Employees Retirement System of Texas. Which institutional investors are buying GALAPAGOS NV/S stock? GLPG stock was purchased by a variety of institutional investors in the last quarter, including Public Employees Retirement Association of Colorado, 1832 Asset Management L.P., Acadian Asset Management LLC, Barclays PLC, Jane Street Group LLC, Russell Investments Group Ltd., Geode Capital Management LLC and Goldman Sachs Group Inc.. How do I buy shares of GALAPAGOS NV/S? Shares of GLPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is GALAPAGOS NV/S's stock price today? One share of GLPG stock can currently be purchased for approximately $216.42. How big of a company is GALAPAGOS NV/S? GALAPAGOS NV/S has a market capitalization of $11.86 billion and generates $375.54 million in revenue each year. The biotechnology company earns $-34,560,000.00 in net income (profit) each year or ($0.66) on an earnings per share basis. View Additional Information About GALAPAGOS NV/S. What is GALAPAGOS NV/S's official website? The official website for GALAPAGOS NV/S is http://www.glpg.com/. How can I contact GALAPAGOS NV/S? GALAPAGOS NV/S's mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The biotechnology company can be reached via phone at 321-534-2900 or via email at [email protected] MarketBeat Community Rating for GALAPAGOS NV/S (NASDAQ GLPG)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 414 (Vote Outperform)Underperform Votes: 359 (Vote Underperform)Total Votes: 773MarketBeat's community ratings are surveys of what our community members think about GALAPAGOS NV/S and other stocks. Vote "Outperform" if you believe GLPG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLPG will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/28/2020 by MarketBeat.com StaffFeatured Article: What is the S&P/ASX 200 Index?
